DE10102977A1 - Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose - Google Patents

Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose

Info

Publication number
DE10102977A1
DE10102977A1 DE10102977A DE10102977A DE10102977A1 DE 10102977 A1 DE10102977 A1 DE 10102977A1 DE 10102977 A DE10102977 A DE 10102977A DE 10102977 A DE10102977 A DE 10102977A DE 10102977 A1 DE10102977 A1 DE 10102977A1
Authority
DE
Germany
Prior art keywords
clc
nucleic acid
substances
chloride
channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE10102977A
Other languages
German (de)
English (en)
Inventor
Thomas Jentsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE10102977A priority Critical patent/DE10102977A1/de
Priority to PCT/DK2002/000038 priority patent/WO2002059612A2/en
Priority to AU2002224759A priority patent/AU2002224759A1/en
Priority to EP02715379.0A priority patent/EP1360204B1/en
Priority to JP2002559678A priority patent/JP4138485B2/ja
Publication of DE10102977A1 publication Critical patent/DE10102977A1/de
Priority to US10/622,377 priority patent/US7534425B2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE10102977A 2001-01-23 2001-01-23 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose Pending DE10102977A1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE10102977A DE10102977A1 (de) 2001-01-23 2001-01-23 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose
PCT/DK2002/000038 WO2002059612A2 (en) 2001-01-23 2002-01-17 Animal model and cell-line expressing modified chlorine channel
AU2002224759A AU2002224759A1 (en) 2001-01-23 2002-01-17 Animal model and cell-line expressing modified chlorine channel
EP02715379.0A EP1360204B1 (en) 2001-01-23 2002-01-17 Process for the development of therapeutic agents, in particular active compounds for the treatment of osteoporosis
JP2002559678A JP4138485B2 (ja) 2001-01-23 2002-01-17 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム
US10/622,377 US7534425B2 (en) 2001-01-23 2003-07-18 Animal model and cell-line expressing modified chlorine channel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10102977A DE10102977A1 (de) 2001-01-23 2001-01-23 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose

Publications (1)

Publication Number Publication Date
DE10102977A1 true DE10102977A1 (de) 2002-08-01

Family

ID=7671497

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10102977A Pending DE10102977A1 (de) 2001-01-23 2001-01-23 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose

Country Status (6)

Country Link
US (1) US7534425B2 (cg-RX-API-DMAC7.html)
EP (1) EP1360204B1 (cg-RX-API-DMAC7.html)
JP (1) JP4138485B2 (cg-RX-API-DMAC7.html)
AU (1) AU2002224759A1 (cg-RX-API-DMAC7.html)
DE (1) DE10102977A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002059612A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420830A1 (en) * 2010-08-16 2012-02-22 Forschungsverbund Berlin e.V. Chloride transporter ClC-7 and cell-based screening method

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002224758A1 (en) * 2001-01-23 2002-08-06 Nordic Bioscience A/S Method for screening compounds for activity in treating an osteoclast related bone disease
US20030215787A1 (en) * 2002-01-23 2003-11-20 Wen-Pin Yang Modulators of the CLC-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
EP1471818A4 (en) 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
GB0227243D0 (en) * 2002-11-21 2002-12-31 Univ Aberdeen Genetic markers for bone mass
US7785807B2 (en) * 2004-12-13 2010-08-31 Monell Chemical Senses Center Voltage-gated, pH-sensitive anion channel and its novel splice variant involved in taste sensation
WO2008101022A2 (en) * 2007-02-13 2008-08-21 The Nielsen Company (Us), Llc Methods and apparatus to reach through to business logic services
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
US11060060B2 (en) 2015-09-16 2021-07-13 University of Pittsburgh—of the Commonwealth System of Higher Education Method of making trabecular bone
US10640766B2 (en) * 2017-04-12 2020-05-05 Tempo Bioscience, Inc. Biosensors for chloride ions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434058A (en) * 1993-02-09 1995-07-18 Arch Development Corporation Apolipoprotein B MRNA editing protein compositions and methods
WO1999016909A1 (en) * 1997-10-01 1999-04-08 Yale University Methods to modulate blood pressure and diagnose bartter's syndrome type iii
EP1514867A3 (en) 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:NM_001829 *
Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:X83378 *
Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:XM_010391 *
Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:Z67744 *
STN-Recherche am 18.05.01 Biosis-Abstr. 1999:86968FRIEDRICK, T., BREIDERGOFF, T., JENTSCH, T.J.: Mutational analysis demonstrates that C1C-4 and C1C-5 directly mediate plasma membrane currents. 1999. In: Journal of Biological Chemestry, Vol. 274, S. 896-902 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420830A1 (en) * 2010-08-16 2012-02-22 Forschungsverbund Berlin e.V. Chloride transporter ClC-7 and cell-based screening method

Also Published As

Publication number Publication date
EP1360204A2 (en) 2003-11-12
JP2004531227A (ja) 2004-10-14
WO2002059612A3 (en) 2002-12-12
US7534425B2 (en) 2009-05-19
US20040265837A1 (en) 2004-12-30
JP4138485B2 (ja) 2008-08-27
EP1360204B1 (en) 2014-04-30
WO2002059612A2 (en) 2002-08-01
AU2002224759A1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
Taniguchi et al. Disruption of semaphorin III/D gene causes severe abnormality in peripheral nerve projection
Young, 3rd et al. Transgenesis and the study of expression, cellular targeting and function of oxytocin, vasopressin and their receptors
DE69233477T2 (de) Transgene nicht-menschliche tiere ohne prionprotein
Strittmatter et al. Neuronal pathfinding is abnormal in mice lacking the neuronal growth cone protein GAP-43
US8871996B2 (en) Mice expressing human voltage-gated sodium channels
DE69534310T2 (de) Ptc gene und ihre verwendung
US8486647B2 (en) Neuropeptide release assay for sodium channels
Levine et al. Period protein from the giant silkmoth Antheraea pernyi functions as a circadian clock element in Drosophila melanogaster
Periz et al. Ca2+‐ATPase function is required for intracellular trafficking of the Notch receptor in Drosophila
JP4138485B2 (ja) 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム
EP1137810A2 (de) Peptid screening test zum nachweis von ass
US20090100532A1 (en) Transgenic mice expressing hypersensitive nicotinic receptors
US6753456B2 (en) Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dopaminergic pathology and increased anxiety
DE60313499T2 (de) Mutante nichtmenschliche säuger mit sigmarezeptormangel und anwendungen dafür
JP2003513645A (ja) メラノコルチン−3レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法
DE69920698T2 (de) Transgenes nichthumanes tier mit inaktivem peg3 und dessen verwendung
US20050044581A1 (en) Animals and cells containing a mutated alpha2/omega1 gene
EP2579039B1 (en) Neuropeptide release assay for sodium channels
Guo The identification and characterization of the Drosophila GTPase dMiro and the role of presynaptic mitochondria for synaptic function
WO2001068698A2 (de) Nichtselektiver kationenkanal
Dickey Role of pp2a/bβ2 and pka/akap1 in brain development and function via dynamin-related protein 1 (drp1) control of mitochondria shape and bioenergetics
Reppert et al. Period Protein from the Giant Silkmoth Antheraea pernyi Functions as a Circadian Clock Element in Drosophila melanogaster
HK1178252A (en) Neuropeptide release assay for sodium channels
HK1178252B (en) Neuropeptide release assay for sodium channels
HK1185943B (en) Neuropeptide release assay for sodium channels

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law